Here’s an overview of some of last week’s most interesting news, articles, interviews and videos: Malware spread through ...
Transformer on MSNOpinion
Policy can still work on short timelines
Transformer Weekly: California makes a bid to regulate AI, a new FRONTIER ACT, and Anthropic’s record-breaking IPO ...
Pharmaceutical Technology on MSN
Recursion CEO details novel Phase III endpoint for rare disease drug
The AI-driven biotech has secured FDA alignment on a pivotal trial for its FAP therapy, with a study start planned for 2027.
If you checked your bank balance, booked a flight or ordered groceries online today, there is a good chance your request was ...
Spread the loveAlright, let’s talk about Java. Specifically, let’s talk about Java and the kind of headaches it can cause ...
REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no ...
Recursion Pharmaceuticals, Inc. ( RXRX) announced Wednesday that it has reached alignment with the U.S. Food and Drug Administration (FDA) on the design of its registrational Phase 3 trial of REC-4881 ...
Recursion Pharmaceuticals said on November 18, 2026 that it had aligned with the U.S. Food and Drug Administration on a ...
Recursion announces FDA alignment for REC-4881’s Phase 3 trial in familial adenomatous polyposis, targeting crucial adenoma excision outcomes.
REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies. Its potential as a first-in-class oral therapy ...
In the field of artificial intelligence, machine learning is a branch that uses data and algorithms to imitate human learning. It's an ongoing process in which computers can improve their accuracy ...
Java4Shell (CVE-2026-114938) is a critical OpenJDK Base64 decoder bug that can lead to RCE. See who’s affected, how to check ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results